Drugs / MNK-6105
last change Jul 2025 re-read 2 minutes ago

MNK-6105

Developed for
hepatic encephalopathy
Investigated by
Mallinckrodt

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT04128462 Nov 2021 → Apr 2025 hepatic encephalopathy Mallinckrodt Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MNK-6105 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04128462
Route Intravenous “continuous intravenous (IV) infusion” NCT04128462